ATE437884T1 - Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen - Google Patents

Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen

Info

Publication number
ATE437884T1
ATE437884T1 AT04753565T AT04753565T ATE437884T1 AT E437884 T1 ATE437884 T1 AT E437884T1 AT 04753565 T AT04753565 T AT 04753565T AT 04753565 T AT04753565 T AT 04753565T AT E437884 T1 ATE437884 T1 AT E437884T1
Authority
AT
Austria
Prior art keywords
gpc
alzheimer
disease
glycerophosphocholine
derivatives
Prior art date
Application number
AT04753565T
Other languages
English (en)
Inventor
Jay W Pettegrew
Richard J Mcclure
Kanagasabai Panchalingam
Billy W Day
Original Assignee
Jay W Pettegrew
Richard J Mcclure
Kanagasabai Panchalingam
Billy W Day
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jay W Pettegrew, Richard J Mcclure, Kanagasabai Panchalingam, Billy W Day filed Critical Jay W Pettegrew
Application granted granted Critical
Publication of ATE437884T1 publication Critical patent/ATE437884T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04753565T 2003-05-29 2004-05-27 Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen ATE437884T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47418203P 2003-05-29 2003-05-29
US10/854,894 US7815894B2 (en) 2003-05-29 2004-05-27 Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
PCT/US2004/016750 WO2004110963A2 (en) 2003-05-29 2004-05-27 Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
ATE437884T1 true ATE437884T1 (de) 2009-08-15

Family

ID=33457562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04753565T ATE437884T1 (de) 2003-05-29 2004-05-27 Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen

Country Status (6)

Country Link
US (1) US7815894B2 (de)
EP (1) EP1641806B1 (de)
CN (1) CN1795198B (de)
AT (1) ATE437884T1 (de)
DE (1) DE602004022301D1 (de)
WO (1) WO2004110963A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329142B2 (en) * 2003-05-29 2012-12-11 Pettegrew Jay W Compounds, compositions and methods for medical imaging of Parkinson's disease
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
CA2559723C (en) * 2004-03-18 2010-02-23 Transtech Pharma, Inc. Fluorescence polarization assay related applications
CN102525992A (zh) * 2012-03-09 2012-07-04 徐奎 L-α-甘油磷酸胆碱薄膜衣片及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US394841A (en) * 1888-12-18 Carl duisberg
US401024A (en) * 1889-04-09 Benfabriken
US329638A (en) * 1885-11-03 Fabriken
US622961A (en) * 1899-04-11 Ivan levinstein and carl mensching
US1979534A (en) * 1931-10-15 1934-11-06 Farastan Company Disazo compound for therapeutic use
FR2398046A1 (fr) * 1977-07-18 1979-02-16 Inst Francais Du Petrole Synthese enzymatique de la l-carnitine
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US4642290A (en) * 1982-12-06 1987-02-10 Sih Charles J Process for preparing a compound for use in the production of L-carnitine
JPS59192095A (ja) * 1983-04-13 1984-10-31 Ajinomoto Co Inc Ｌ−カルニチンの製造法
US4542098A (en) * 1983-05-06 1985-09-17 Institut Francais Du Petrole Production of glucose dehydrogenase and use of the resultant enzyme in the enzymatic synthesis of L-carnitine
DD221905B1 (de) * 1983-11-03 1987-03-18 Univ Leipzig Verfahren zur herstellung von l(-)-carnitin und seinen derivaten
FI86889C (fi) * 1984-03-29 1992-10-26 Lonza Ag Foerfarande foer framstaellning av av l-karnitin pao mikrobiologiskt saett
IT1177874B (it) * 1984-07-04 1987-08-26 Sigma Tau Ind Farmaceuti Estere della acetil carnitina,procedimenti per la sua preparazione e composizioni farmaceutiche che lo contengono
CH664374A5 (de) * 1985-02-27 1988-02-29 Lonza Ag Verfahren zur herstellung von l-carnitin auf mikrobiologischem weg.
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5039511A (en) * 1987-04-08 1991-08-13 Salutar, Inc. Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
US5008099A (en) * 1987-04-08 1991-04-16 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US4965364A (en) * 1988-02-23 1990-10-23 Massachusetts Institute Of Technology Ligand-accelerated catalytic asymmetric dihydroxylation
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
US5853985A (en) * 1988-08-30 1998-12-29 Bayer Aktiegsesellschaft Promoter of the gene for the human precursor of the alzheimer's disease and its use
US5066583A (en) * 1988-12-21 1991-11-19 Wisconsin Alumni Research Foundation Method for distinguishing alcoholics from non-alcoholics
JP3059735B2 (ja) * 1989-10-13 2000-07-04 旭化成工業株式会社 Ｌ―カルニチンデヒドロゲナーゼおよびその製造法
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6551576B1 (en) * 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
AU654013B2 (en) * 1991-03-13 1994-10-20 Regents Of The University Of Minnesota 2-hydroxy-3(4-iodophenyl)-1-(4-phenylpiperidinyl) propane
GB9108756D0 (en) * 1991-04-24 1991-06-12 Ici Plc Production of polyalkanoate in plants
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
US6300085B1 (en) * 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) * 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
EP0770400B1 (de) * 1995-10-31 2003-02-26 Japan Science and Technology Corporation Am sekundären Kohlenstoffatom markiertes Acyl-L-Carnitin und diagnostische Mittel es enthaltend
DE69721542D1 (de) * 1996-06-14 2003-06-05 Mclean Hospital Corp In vitro h-nmr-nachweis der häufigkeit und menge von alkoholeinnahme
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6380252B1 (en) * 1996-07-05 2002-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
US6255057B1 (en) * 1996-07-26 2001-07-03 Ernest Gallo Clinic And Research Center Detection of cellular exposure to ethanol
DE69737915T2 (de) * 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US5770324A (en) * 1997-03-03 1998-06-23 Saint-Gobain Industrial Ceramics, Inc. Method of using a hot pressed silicon carbide dummy wafer
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6066664A (en) * 1997-06-06 2000-05-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for decreasing the appetite in bulimic, overweight individuals
IT1291930B1 (it) * 1997-06-18 1999-01-21 Sigma Tau Ind Farmaceuti Composizione riequilibratrice delle turbe dell'umore in individui sani
DE19749480A1 (de) * 1997-11-08 1999-05-20 Univ Leipzig Verfahren zur Herstellung von L-Carnitin aus Crotonobetain
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
TW477702B (en) * 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
DE69914460T2 (de) * 1998-03-04 2004-10-28 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung
IT1299182B1 (it) * 1998-05-29 2000-02-29 Sigma Tau Ind Farmaceuti Procedimento chimico per la sintesi stereoselettiva della r-(-)- carnitina.
IT1299195B1 (it) * 1998-06-25 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
CA2338090C (en) * 1998-07-22 2009-07-14 Metabolix, Inc. Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies
US6337197B2 (en) * 1998-10-27 2002-01-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Coenzymes useful for the synthesis of L-carnitine
ATE290096T1 (de) * 1998-10-27 2005-03-15 Sigma Tau Ind Farmaceuti Coenzym zur herstellung von l-carnitin
US6708053B1 (en) * 1999-03-04 2004-03-16 Science And Technology Corp. @ Unm Biochemical markers of brain function
US6313159B1 (en) * 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US6348464B1 (en) * 1999-11-12 2002-02-19 Guilford Pharmaceuticals, Inc. Pyrrolecarbonylimino derivatives as naaladase inhibitors
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
PL374082A1 (en) 2002-02-07 2005-09-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitine in the treatment of geriatric depression
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
ITRM20020620A1 (it) 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Also Published As

Publication number Publication date
CN1795198A (zh) 2006-06-28
EP1641806B1 (de) 2009-07-29
CN1795198B (zh) 2011-08-17
WO2004110963A3 (en) 2005-03-10
US20040241090A1 (en) 2004-12-02
US7815894B2 (en) 2010-10-19
DE602004022301D1 (de) 2009-09-10
EP1641806A2 (de) 2006-04-05
WO2004110963A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
Désogère et al. Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models
Nahrendorf et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis
Gašperšič et al. Monitoring ankylosing spondylitis therapy by dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging
Bolliger et al. Virtual autopsy using imaging: bridging radiologic and forensic sciences. A review of the Virtopsy and similar projects
Yanagisawa et al. In vivo detection of amyloid β deposition using 19F magnetic resonance imaging with a 19F-containing curcumin derivative in a mouse model of Alzheimer's disease
Jackowski et al. Maximum intensity projection of cranial computed tomography data for dental identification
Patil et al. Curcumin targeted, polymalic acid‐based MRI contrast agent for the detection of Aβ plaques in Alzheimer's disease
NO984543D0 (no) Bioaktiverte diagnostiske imaging kontrastmidler
WO2007044867A3 (en) Imaging agents and methods of use thereof
Shepelytskyi et al. Hyperpolarized 129Xe time-of-flight MR imaging of perfusion and brain function
Snellman et al. In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F] flutemetamol
Santin et al. In vivo detection of amyloid plaques by gadolinium-stained MRI can be used to demonstrate the efficacy of an anti-amyloid immunotherapy
EA201100267A1 (ru) Новые бензофураны, подходящие в качестве предшественников соединений, которые являются полезными для визуализации амилоидных отложений
Kim et al. An aptamer‐based magnetic resonance imaging contrast agent for detecting oligomeric amyloid‐β in the brain of an Alzheimer's disease mouse model
Balassy et al. Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies
Choi et al. Human radiation dosimetry of [18F] AV-1451 (T807) to detect tau pathology
Bauwens et al. Radioiodinated phenylalkyl malonic acid derivatives as pH-sensitive SPECT tracers
ATE437884T1 (de) Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
Morita et al. Complementary roles of tumour specific PET tracer 18F-FAMT to 18F-FDG PET/CT for the assessment of bone metastasis
Alavi et al. Is PET-CT the only option?
Macchi et al. Friar leopold mandic (1866–1942): the computed tomography of the body of a saint
Baltes et al. Detecting amyloid-β plaques in Alzheimer’s disease
GB2592320A8 (en) Dihydrazone compounds having high affinity to AB protein and Tau protein, derivatives thereof and use thereof
RU2008106162A (ru) Способ диагностики глиом и внутримозговых гематом больших полушарий головного мозга
George et al. MR spectroscopy aids diagnosis in subarachnoid space cysticercosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties